Table 3.
Primary outcome by group among patients with severe cases of COVID-19
| Outcome | Pregnant cases (n=29), n/N (%) | Nonpregnant controls (n=80), n/N (%) | Adjusted P value | Adjusted OR (95% CI) |
|---|---|---|---|---|
| Composite morbiditya | 4/29 (13.8) | 4/80 (5.0) | .09 | 3.8 (0.8–18.1) |
| High-flow nasal cannula | 2/29 (6.9) | 2/80 (2.5) | –– | –– |
| BiPAP or CPAP | 1/29 (3.5) | 2/80 (2.5) | –– | –– |
| Intubation or mechanical ventilation | 2/29 (6.9) | 1/80 (1.3) | –– | –– |
| ECMO | 0/29 (0.0) | 0/80 (0.0) | –– | –– |
| Death | 0/29 (0.0) | 0/80 (0.0) | –– | –– |
BiPAP, bilevel positive airway pressure; CI, confidence interval; COVID-19, coronavirus disease 2019; CPAP, continuous positive airway pressure; ECMO, extracorporeal membrane oxygenation; OR, odds ratio.
DeBolt et al. Severe and critical COVID-19 in pregnant vs nonpregnant controls. Am J Obstet Gynecol 2021.
a
Composite morbidity includes the need for high-flow nasal cannula supplementation, noninvasive positive pressure ventilation, intubation or mechanical ventilation, extracorporeal membrane oxygenation, and death.